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Extensive research over the last 50 years has revealed that
cancer is a genetic condition in which a cell loses its genomic
integrity. Tumorigenesis is associated with the accrual in
cells of multiple genomic alterations. Base substitutions can
inactivate tumor suppressor genes or cause constitutive acti-
vation of proto-oncogenes. Alternative mechanisms of
tumorigenesis include large genomic deletions, large and
small intragenic deletions, chromosomal translocations,
aberrant promoter methylation and other epigenetic events.
These alterations allow the cell to escape the normal tissue-
dependent restraints on growth and differentiation that may
be cell-autonomous or cell-dependent. It has been proposed
that the accumulation of genetic abnormalities enables the
cell to escape the physiological tissue framework by the
acquisition of six essential cell-transformation traits:
growth-signal autonomy; evasion of apoptosis; insensitivity
to growth-inhibitory signals; sustained angiogenesis; limit-
less replicative potential; and the capacity to invade and
grow metastatically [1]. The molecular aberrations and cellu-
lar mechanisms required to effect these cellular phenotypes
no doubt vary greatly between different types of tumor, and
even within tumor types classified by current histopathology
as similar. Furthermore, the molecular route by which the
tumor cell achieves certain biological endpoints may be as
important as the endpoints themselves in terms of clinical
prognosis and response to therapy.
The accurate diagnosis and classification of tumors is thus of
fundamental clinical importance both as a prognostic indicator
and as the determinant of the most effective treatment
modality. Although the current basis of tumor taxonomy is
tumor grade, stage and type in conjunction with other
histopathological indices, it is becoming increasingly appar-
ent that an individual’s family history, as an indirect marker
of inherent genetic susceptibility, also provides valuable
prognostic and therapeutic indicators, both for the patient
and for their extended family. The research attempting to re-
classify tumors according to their molecular evolution has
focused mainly on breast cancer, the commonest form of
female cancer, which affects one in eight women at some-
time in their lives, but the principles discussed here are
equally applicable to all types of cancer, whether of child-
hood or adult onset. 
Major breast-cancer susceptibility genes 
Although the majority of cancers are ‘sporadic’, occurring in
individuals with no family history of the condition, 20% of
all colorectal and 30% of breast cancer patients have some
family history of the condition, which in itself confers one of
the strongest risk factors for developing the disease; for
example, there is a two-fold increase in breast cancer in first
degree relatives of the index case [2]. In approximately 5% of
breast cancer cases the individual is found to be part of a
large multi-case ‘cancer family’, in which the genetic predis-
position to cancer is inherited as a single autosomal domi-
nant trait, due in the majority of cases to a germ-line
heterozygous mutation in either BRCA1 or  BRCA2 [3,4].
Abstract
Molecular profiling of the transcripts or proteins within an individual tumor may in future provide
important prognostic and therapeutic clinical information both for the affected individual and for
their extended family, but for the time being traditional genetics and pathology retain their place in
the clinic. Both these genes have products that appear to function in
pathways involved in DNA repair, gene transcription and
chromatin structure [5,6]. In each case the mutant suscepti-
bility allele is inherited as an autosomal dominant germ-line
trait, whilst transformation occurs as a recessive phenotype
after loss of the wild-type allele in the transformed cell [7,8].
Importantly, the presence of a germ-line BRCA mutation
does increase the possibility of the patient developing both
ipsilateral and contralateral breast disease and other distinct
tissue-specific tumors, such as male breast cancer, pancre-
atic and prostate cancer in the case of a BRCA2 mutation [9],
and ovarian cancer in the case of a BRCA1 mutation [10].
The tissue-specific nature of the cancer predisposition seen
in the inherited cancer syndromes has yet to be explained.
The discovery of a germ-line BRCA mutation in a family
means that predictive testing can be offered to unaffected
individuals. On the basis of an estimation of their risk, afforded
by predictive testing, such individuals can make better-
informed decisions as to surveillance regimes, prophylactic
surgery (mastectomy and/or salpingo-oophorectomy) or
experimental chemoprevention strategies such as tamoxifen.
The corollary of this is that mutation-negative patients
within these families can be reassured that they are at
normal population risk and can be withdrawn from high-risk
screening programs.
The prognostic significance of a BRCA mutation is still
unclear for breast cancer, when it is separated from indirect
effects such as earlier age of onset, or higher mitotic index
and the higher histopathological grade associated with
BRCA1 tumors [11-14], although it appears to be an indicator
of good prognosis in ovarian cancer [15,16]. Studies prospec-
tively addressing this question are still ongoing. Interest-
ingly, however, recent insights into BRCA2 [17] and BRCA1
[18] protein function, respectively, suggest that this group of
breast tumors may not respond as well to taxanes, a current
common chemotherapeutic agent, or indeed may be more
sensitive to cisplatin than is sporadic breast cancer. These
mechanistically driven hypotheses have yet to be shown to
have clinical significance.
Knowing the BRCA status of a breast tumor has important
clinical implications not only for the affected individuals
themselves but also for their extended family. Unfortunately,
the current means of ascertaining the BRCA status of tumors
is dependent on the prospective identification of genetically
predisposed families on the basis of their large multi-case
affected kinships. Recently, however, with completion of the
Human Genome Project comes the potential for ‘reverse
genetic diagnosis’, based on the genetic phenotype of the
tumors themselves, independent of family structure. 
Redefining tumor taxonomy
Since completion of the draft human genome sequence,
there has been great interest in identifying novel diagnostic,
prognostic and potential therapeutic markers by establishing
the genome-wide expression profiles (transcriptomes) of
various tumor groups; this has been achieved through the
rapid adoption of high-throughput microarray technologies.
This type of approach is in contrast to the previous, labor-
intensive candidate-gene-based approaches and has the
major advantage of potentially measuring simultaneously
the expression of all human genes and not merely a pre-
selected, and thus biased, subgroup. The cancer phenotype is
only partially described by its transcriptome, however, as
functional protein levels are also modulated by post-transla-
tional modifications. 
Somatic mutations in the BRCA genes are not found in spo-
radic breast cancers. This is in contrast to the molecular
pathology of mutations in other cancer-predisposition genes,
such as the familial adenomatous polyposis (APC),
retinoblastoma (RB1) and P53 tumor suppressors, and sug-
gests that breast tumors arising in cells with a heterozygous
BRCA mutation may form a distinctive pathological group.
Down-regulation of BRCA1 transcription has been noted in a
few cases of sporadic breast cancer and found to correlate
with epigenetic methylation of the BRCA1 promoter [19].
This epigenetically mediated diminution in gene expression
in sporadic tumors has not been shown with BRCA2 [20]. It
is significant, then, that gene-expression profiles [21,22] of
BRCA1- and BRCA2-linked tumors allow them to be distin-
guished and classified separately from a group of sporadic
breast tumors with similar hormone-receptor expression
patterns, emphasizing once more the unique nature of these
tumors. Unfortunately, the BRCA-associated tumor cohort
size is small in the recent studies of gene expression in
breast tumors [21,22]. 
In the case of ovarian cancer, Jazaeri et al. [23] showed that
BRCA1- and BRCA2-associated cancers show distinct gene-
expression profiles, but it is striking that, in comparison with
the results from sporadic breast cancer, sporadic ovarian
cancers displayed an expression motif mimicking the profile
of either a BRCA1- or a BRCA2-linked germ-line ovarian
tumor and do not form a separate third group. These findings
could be explained by postulating that sporadic ovarian
cancer can occur by two major, mutually exclusive pathways
in which the BRCA genes are major players, evidenced by the
loss of heterozygosity occurring at their genomic loci despite
the absence of somatic mutations in BRCA1 or BRCA2. More
intriguingly, these distinct expression profiles could repre-
sent differing cellular origins for the various ovarian tumors.
Germ-line mutations in either the BRCA1 or  BRCA2 gene
could predispose different ovarian cell types to cellular trans-
formation. Germane to this suggestion in ovarian cancer is
the expression profiling of breast cancer samples [24], which
has allowed their stratification into two subtypes - luminal
(similar expression profiles to cells that line the duct and are
implicated in the majority of breast cancer) and basal (similar
expression profiles to cells in the basal epithelium) - hinting
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notable that all the expression profiles from a group of
BRCA1-linked breast tumors fell into the latter, basal sub-
classification, suggesting a possible common, homogenous
cellular origin for BRCA1 breast tumors [25]. These profile
classifications were also found to have prognostic signifi-
cance, as the tumors with a basal signature had a poorer
prognosis than the luminal group. These results would
suggest that a unique gene-expression signature may be one
possible mechanism for the identification of BRCA1- and
BRCA2-type breast tumors in families for which a detailed
family history is not known or is small.
Microarray profiling has also been successfully used to delin-
eate gene-expression signatures associated with poor clinical
outcome [22,26], response to neoadjuvant therapy [27] and
a priori potential to metastasis [28]. This latter finding runs
contrary to current belief that primary tumors grow locally
and evolve with time into aggressive tumors capable of
metastasis. The common expression signature indicative of
metastatic potential was delineated over a range of different
tumor tissue types and thus would suggest that metastatic
capacity is already inherent in the primary tumor at first
diagnosis; this finding, if clinically substantiated, could form
the basis of tailoring post-operative adjuvant treatment to
individual tumor genotypes. 
The clinical implications of this large body of research, both
in identifying familial breast cancers from the larger cohort of
sporadic tumors and in finding prognostic molecular markers
for tailoring future therapy, are potentially huge. Even with
conservative estimates of their influence on the identification
of future novel therapeutic markers, gene-expression signa-
tures would allow a more focused, targeted application of the
treatment regimes currently available. But such a radical
change in clinical emphasis from empiric treatment regimes
to those based on individual tumor-specific molecular
markers is highly dependent on our ability to take transcrip-
tion profiles and translate them into a simple, fast, cost-
effective and highly robust clinically applicable form.
Alternatively, it may well be that, once the dust has settled
from the microarray explosion, gene-expression motifs will
emerge that directly correlate with protein levels and would
therefore be amenable to immunohistochemical approaches,
which are already in widespread use in pathology depart-
ments. One example of this would be to identify the basal
breast cancer subgroup associated with poor prognosis [24]
by means of keratin 5/6 and keratin 17 immunostaining. 
Validation of protein expression on multiple paraffin-
embedded tumor samples can be achieved easily and
cheaply through the use of tissue microarrays. These com-
prise core samples of multiple individual tumors embedded
and sectioned onto an individual slide; this has the effect of
reducing the cost of the test and of intra-sample variation.
Numerous studies [29,30] have validated the use of between
one and four core 0.6 mm biopsies, rather than immuno-
staining of the whole tissue section as is current practice in
pathology departments. Tissue arrays can contain multiple
different tumor types, collections of histologically similar
tumors with different clinical prognosis (based on clinical
follow-up data), or samples representing different stages in
tumor progression. This approach is highly dependent on
the capacity to reduce a highly complex gene-expression
profile to a feasibly small protein profile, the availability of
antibodies and the ability to assay expression of the relevant
proteins in a quantifiable manner. 
Identifying novel tumor-susceptibility genes 
To date, classical linkage analysis and candidate-gene
approaches have yet to identify the genetic cause of the 80%
of familial moderate- to high-risk breast cancer families not
associated with BRCA mutations or another familial breast
cancer syndrome (Table 1). This is due wholly or in part to
complications from genetic heterogeneity, low penetrance or
polygenic mechanisms. Arguably, the clustering of breast
cancer seen in these families could be due to environmental
factors, but twin studies [31] and the pattern of inheritance
[32] would point towards a genetic susceptibility (although
the two models are not mutually exclusive). A recent model
[33] based on population and multi-case non-BRCA breast
cancer families suggested a polygenic mode of inheritance in
which genetic susceptibility is the product of multiple low- to
moderate-penetrance alleles; this model predicts that half of
all breast cancers will arise in the most susceptible 12% of
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Table 1 
Breast cancer susceptibility syndromes
Syndrome Gene(s) responsible Other main tumor types
Familial breast and ovarian cancer syndrome BRCA1 and BRCA2 Ovary, prostate and pancreas
Li-Fraumeni syndrome P53 Sarcoma and brain
Cowdens syndrome PTEN Thyroid and endometrial
Mismatch repair syndrome MLH1 and MSH2 Gastrointestinal
Peutz-Jegher syndrome STK11 Gastrointestinal
Genome Biology 2004, 5:113 the population. If this susceptible population could be iden-
tified, it would have major clinical implications for the most
effective targeting of population surveillance regimes.
Attempts to identify low-penetrance genes have used candi-
date-gene-based linkage-disequilibrium approaches, focus-
ing on polymorphisms that may either be causally related to
the cancer risk or are in strong linkage disequilibrium with
the disease-causing variants in breast cancer patients com-
pared with unaffected controls. Common polymorphisms in
candidate breast cancer genes have been studied by looking
for an association between a common polymorphism in a
candidate gene and breast cancer in a large series of affected
individuals compared to an age- and ethnicity-matched
unaffected control group. Unfortunately, many studies
appear contradictory in their conclusions, whilst the size of
many studies may also preclude the identification of low-
penetrance genes. Possible low-penetrance alleles have been
identified in the estrogen-metabolism gene CYP19, the
carcinogen-metabolism gene GSTP1, and the general tumor-
suppressor P53, each of which confers 1.2- to 2-fold increase
in the relative risk of developing breast cancer [34]. Other
studies have included common variants of BRCA1 [35] and
other genes implicated in DNA repair [36]. Indeed the
1100delG polymorphism in the DNA-repair gene CHK2, first
described in a family with Li-Fraumeni syndrome (see
Table 1), has been found to cause a 1.7-fold relative risk of
familial breast cancer. Interestingly, however, this increased
risk is not found in families with a known BRCA mutation,
suggesting an epistatic overlap in function between these
proteins [37,38]. The relative lack of success of the candi-
date-gene approach underlines our lack of knowledge of
normal breast tissue physiology, cell biology and the mecha-
nism of cellular transformation. The choice of candidate
genes for screening is at best speculative. There is a need to
identify novel candidate tumor-susceptibility genes without
the bias of our current knowledge of the pathways involved
in tumorigenesis, or to attempt non-hypothesis-driven
genome-wide linkage-disequilibrium studies [39,40]. 
An alternative approach to identifying novel tumor suppres-
sor genes has involved interrogation of the transformed
genome of established tumors. The Cancer Genome Project
[41], based at the Wellcome Trust Sanger Institute (Hinxton,
UK), is using the information and high-throughput tech-
nologies established by the Human Genome Project to char-
acterize large genomic homozygous deletions and somatic
mutations in an initial panel of 48 common adult epithelial
tumors, as a means of identifying novel genetic events
important in carcinogenesis. This approach will produce an
extremely detailed unbiased description of the transformed
genome. Alterations found in the initial panel of tumors will
be sought in a larger tumor cohort. In addition, further cell-
biological investigation will be required to separate those
aberrations that are causative in nature from those that
merely correlate with tumorigenesis. Array comparative
genomic hybridization (array CGH) can also be used to identify
chromosomal gains and losses within tumor cells, with a
high resolution even in the presence of 60% normal cell
contamination [42]. This makes it an excellent technique for
the identification of chromosomal events early in tumor
formation and, used in conjunction with human genome
sequence, can generate a list of candidate genes very quickly. 
What are the rate-limiting steps?  
The completion of the Human Genome Project marked a
paradigm shift in human genetic research. The knowledge of
the human genome sequence allows in theory the characteri-
zation of all genomic diversity in both disease-associated
and non-disease-associated genomes. This information, in
association with high-throughput technologies, has allowed
non-hypothesis-driven interrogation of tumor phenotypes at
both the genomic and gene-expression levels. Proteomic
research has not been considered in this article, but it consti-
tutes the next descriptive level being pursued in ‘transla-
tional’ research that aims to bring the insights of the lab
bench to bear on clinical practice. Unlike previous
approaches, genome-wide scans have the advantage of
painting a picture based on unbiased, non-pre-selected data
points but - like pointillistic images - if viewed too closely the
abundance of primary brushstrokes will obscure the actual
image. The interpretation and reproducibility of the data
thus become key rate-limiting steps. These problems will be
solved by establishing functional, biological assays through
which observational data can be filtered. When considering
tumors, functional biological assays include establishing bio-
logically relevant, mechanistically defined end-points in
patient treatment and response. From a clinical perspective,
substratification of tumors is only relevant if it can be
achieved within a time scale relevant to the patient’s care
and, more importantly, can have a significant clinical impact
on either treatment or prognosis. Similarly, the identifica-
tion of low-penetrance genetic susceptibility alleles will only
become clinically important if intervention, either at the
environmental/behavioral level or by population surveil-
lance, becomes a feasible reality both from the practical and
the financial points of view. At present, for example, the clin-
ical utility of the CHK2 1100delG allele, conferring a two-
fold increase in breast cancer but present in 1.1% of the
normal population, is extremely limited.
It is becoming evident that the current models used in
cancer genetics studies for defining and using information
about familial cancer risk will see a radical change as our
knowledge increases. It will be interesting to see whether, in
the next decade, current genetic practice will be turned on its
head and ‘reverse genetic diagnostics’ will mean that tumor
phenotype will alert us to increased family risk. The ethical
implications of this approach in terms of informed consent
and pre-test counseling for clinical diagnostic tests that may
have wider genetic implications for unaffected relatives will
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Genome Biology 2004, 5:113need to be addressed. Genome-wide unbiased approaches
are already beginning to shed light both on the genetic
changes that give rise to tumors and on the expression pro-
files that characterize established tumors with different
origins and different prognoses. As these findings move ever
closer to having specific implications for individual patients
and their families, we will face new challenges in interpreting
and applying them in the clinic. 
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